Blafar is focused on the research and development of high quality and frontier functionalised biopolymers and their formulations for cosmetics, personal care and biomedical/biological applications. Our technologies for the design and development of such innovative raw materials will provide advanced functionalised biopolymers, including functionalised hyaluronic acid, chondroitin sulfate, gelatin and collagen and their derivatives for improved outcomes in biomedical applications. We also design and develop synthetic hyperbranched PEG-based biocompatible polymers for bio-applications.

Injectable therapeutics enabled by engineered biomaterials are becoming increasingly popular, transforming traditional clinical practice into a minimally invasive and regenerative regime. Injectable hydrogels have been used to deliver a variety of cargo molecules, including growth factors, chemokines and therapeutic cells to promote tissue/organ regeneration. The products that Blafar develops have many advanced properties and unique selling points over current products on the market. The products also provide a promising alternative to replace the traditional therapeutic approaches and perform outstanding outcomes, such as in cell/drug delivery system, 3D printing, 3D cell culture, and scaffolds for tissue repair and regeneration. All these advantages are based on the well-designed manufacturing patented technologies that Blafar possesses.

We anticipate to significantly grow our market share and expand the product line of our existing biomaterials products. We will also further design and develop formulations using our multifunctional biomaterials and aim to bring our injectable scaffold and 3D bio-ink products to the market. It is anticipated that Blafar can grow at a fast pace because of the leadership of Professor Wenxin Wang and the highly skilled technical team as well as the solid foundation of the new technologies. We have filed three patents for our technology. We have also licensed three new patented technologies from UCD. Blafar will continually engage in research and innovation to develop new biomaterial products.

Blafar has been engaging with several projects funded by Irish Funding Agencies (such as IRC and SFI) to realise the potential impact of our biopolymer technologies on improving the quality of the lives of patients worldwide.




Blafar has also participated in several research projects funded under Horizon 2020-EU. The brief introduction of each project is shown as follow.

HyMedPoly aims to develop new therapies based on biomedical polymers and inorganic materials. A group of 9 universities and companies from across Europe are creating a cohort of 15 Early Stage Researchers (ESRs) for the development of new materials (such as biopolymers, bioceramics and bioactive glasses) with antibacterial capacity for biomedical applications. The new material systems are aimed at applications such as wound management, implants and biofilm prevention. Each ESR is receiving a practical training programme through state-of-the-art research projects at world-class academic institutes and companies and is addressing key issues that determine the future new therapies of antibacterial materials. Blafar Ltd. develops biopolymers using modern chemistry and polymer chemistry approaches. The polymers obtained are used as antibacterial biomaterials for wound healing.

Find More >>